Xeno-Free Biologics Facility in Cancún, Now Producing and Distributing Six Product Lines to International Markets

COFEPRIS-Guided Laboratory Actively Shipping Exosomes, MSCs, NK Cells, and Allogeneic Fibroblasts as Company Advances Authorized Distributor Program and 2026 Pipeline Expansion Including Peptide Formulations, Secretome, and Private-Label Manufacturing

LAS VEGAS, NV / July 14th, 2026 / Regenerative Medical Technologies Group, Inc. (the “Company”) (OTCID:RMTG), a global leader in regenerative medicine solutions, today announced through its Global Stem Cells Group (GSCG) subsidiary that the Cellgenic advanced biologics manufacturing facility in Cancún, Mexico, has officially commenced full operations.

The Laboratory – believed to be the first facility in Cancún developed specifically for the external manufacturing and international distribution of biologics – is now actively producing and shipping six biologic product lines to authorized medical professionals and institutions across compliant international markets. The operational launch follows the facility’s soft opening during the ISSCA Global Regenerative Medicine Summit in September 2025, which attracted full attendance from physicians and scientists representing more than 30 countries.

The full-scale launch adds a significant manufacturing revenue stream to RMTG’s integrated business model and builds on the Company’s recent financial momentum, including Q1 2025 sales of $1.35M representing 67% growth year-over-year with operational profits of $134,000.

“This facility reflects years of deliberate planning and represents a pivotal milestone in our expansion strategy,” said David Christensen, CEO and President of RMTG. “Our goal has never been rapid expansion without structure. We built this laboratory to support physicians and institutions seeking consistent, well-documented biologics produced under carefully designed conditions – and we are now delivering on that commitment. We believe the addition of in-house manufacturing capability significantly strengthens our competitive position and our ability to generate recurring revenue across our 30-plus-country distribution network.”

Six Active Product Lines in Production

As of January 2026, the Cancún facility is actively producing and distributing the following biologic products to authorized professionals and institutions:

• Exosome Flow Series – Liquid exosomes available in multiple concentrations
• Lyophilized Exosomes – Prepared for topical and localized applications
• Umbilical Cord-Derived Mesenchymal Stem Cells (MSCs) – Cryopreserved and culture-expanded
• Natural Killer (NK) Cells – Produced under controlled freezing and handling protocols
• Allogeneic Fibroblasts – Intended for aesthetic and research-oriented applications
• Sterile Diluents – Including bacteriostatic water and saline solutions

All products are accompanied by full batch documentation, donor screening records, and handling guidelines. The facility incorporates modular cleanroom environments, controlled cold-chain logistics, structured batch documentation, and donor traceability systems developed with reference to AATB-aligned practices and COFEPRIS-guided operational frameworks. Cellgenic emphasizes that its biologics are not intended to diagnose, treat, cure, or prevent any disease and are supplied exclusively to authorized professionals and institutions in compliance with local regulations.

Xeno-Free Manufacturing: A Differentiating Standard

All biologics produced at the Cancún facility are manufactured under xeno-free conditions, meaning no animal-derived components are used at any stage of production. Cellgenic’s manufacturing philosophy emphasizes human-origin materials, controlled inputs, and fully documented sourcing processes – an approach the Company believes supports broader international acceptance and alignment with evolving regulatory expectations across multiple regions.

Benito Novas, CEO of Global Stem Cells Group and founder of Cellgenic, added: “This is what we set out to build – purpose-built infrastructure, not repurposed spaces. Physicians around the world are asking for consistent access to well-documented biologics produced under real manufacturing conditions. This facility delivers on that demand and positions Cellgenic to scale alongside the growing international adoption of regenerative medicine.”

Integrated Model: Manufacturing, Education, and Clinical Collaboration

The facility operates in close coordination with the Cellular Hope Institute, a clinical and educational center also based in Cancún under the GSCG umbrella, as well as ISSCA (International Society for Stem Cell Application), the world’s largest organization dedicated to training physicians in regenerative medicine. Through this integrated model, visiting physicians and researchers participating in ISSCA-accredited programs can observe manufacturing workflows firsthand, engage in hands-on educational sessions, and participate in structured clinical discussions related to biologics handling and responsible application.

“We expect this facility to play a meaningful role in our integrated model of manufacturing, education, and clinical collaboration,” said Sarah Barroso, Managing Director of Cellgenic. “By aligning our laboratory operations with the Cellular Hope Institute and ISSCA’s educational platform, we are contributing to greater transparency, consistency, and professional dialogue within the regenerative medicine field.”

2026 Pipeline and Growth Initiatives

Building on the momentum of the operational launch, Cellgenic has outlined an expanded product and services pipeline for 2026, including:

• Exosome-peptide combination formulations
• Multi-peptide blended delivery formats
• Cell-free conditioned media (secretome)
• Cryopreserved cell banking services
• Private-label and white-label manufacturing programs

Authorized Distributor Program

The Company has also introduced an Authorized Distributor Program designed for qualified partners operating in compliant markets. The program is structured to support long-term collaboration through educational resources, standardized documentation, and regional alignment initiatives. RMTG expects the distributor program to serve as a key driver of international growth as the Company scales its manufacturing capacity and geographic reach throughout 2026.

About Regenerative Medical Technologies Group, Inc. (RMTG)

Since the acquisition of Global Stem Cells Group (GSCG), Regenerative Medical Technology Group (RMTG) is focused on Stem Cell and Regenerative Medicine fields, covering clinical research, patient applications, along with physician training through its state-of-the-art global network of companies. The Company’s mission is to enable physicians to make the benefits of stem cell medicine a reality for patients around the world. RMTG has been educating doctors on the science and application of cell-based therapeutics for over 10 years through its professional trademarked association ISSCA (International Society for Stem Cell Application), a global network of medical professionals that leverages multinational relationships to build best practices and further the Company’s mission.

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations, product distribution, manufacturing capabilities, and medical education to capitalize on the rapidly expanding global regenerative medicine market. The Company’s Cellgenic brand offers a comprehensive portfolio of regenerative medicine products including exosomes, MSCs, and platelet-rich plasma kits produced under rigorous quality protocols.

To learn more, visit www.regenmedtechgroup.com and www.stemcellsgroup.com.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. Forward-looking statements include, but are not limited to, statements regarding planned product pipeline expansions, anticipated distributor program growth, expectations for international market penetration, projected manufacturing capacity scaling, and the Company’s broader strategic positioning in the regenerative medicine sector. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and similar expressions are intended to identify forward-looking statements.

As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, manufacturing facility performance, product pipeline development, distributor program enrollment, or international market expansion. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including but not limited to: changes in international regulatory frameworks governing biologics manufacturing and distribution; the Company’s ability to attract and retain authorized distribution partners; the successful development and commercialization of pipeline products; competitive dynamics within the regenerative medicine industry; supply chain disruptions affecting raw materials or cold-chain logistics; the Company’s ability to maintain compliance with applicable local, national, and international regulations; and general economic and market conditions.

The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contact: David Christensen, CEO and President Regenerative Medical Technologies Group, Inc. investor.relations@regenmedtechgroup.com | (800) 956-3935

Cellgenic launches regulated commercial operations in Argentina, creating a platform for biologics distribution, physician education, and regional expansion.

BOCA RATON, FL — April 26, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”), through its wholly owned subsidiary Global Stem Cells Group and its commercial division Cellgenic, today announced a major expansion of its Latin American operations with the establishment of Cellgenic’s commercial platform in Argentina.

The expansion follows the completion of regulatory and operational milestones that allow Cellgenic to commercialize qualifying biologic and regenerative medicine products through licensed medical practitioners in compliance with applicable Argentine regulations.

The Company believes this represents one of the most significant strategic initiatives in Cellgenic’s international growth strategy and positions Argentina to become one of its principal operating hubs for South America.

“Argentina represents a unique opportunity for Cellgenic,” said David Christensen, Chief Executive Officer of Regenerative Medical Technology Group. “The combination of scientific talent, established clinical infrastructure, and a supportive regulatory framework creates an environment where we believe we can significantly expand physician access to advanced regenerative medicine products while building a scalable commercial operation throughout the region.”

Unlike many markets where regulatory uncertainty has limited physician adoption of regenerative medicine products, Cellgenic’s operational platform is designed to provide physicians with compliant access to high-quality biologic products supported by education, technical resources, and commercial infrastructure.

As part of the expansion, Cellgenic expects to:

• Expand its commercial sales organization throughout Argentina;
• Conduct physician education conferences, workshops and certification programs in collaboration with ISSCA;
• Develop new clinical collaborations and scientific case studies;
• Increase physician adoption of regenerative medicine products;
• Expand distribution capabilities throughout Argentina and neighboring Latin American markets; and
• Establish Argentina as one of Cellgenic’s primary regional centers for future growth.

The Company believes that regulatory compliance, physician education, and commercial infrastructure are critical components required for widespread adoption of regenerative medicine technologies. By integrating these elements into a unified operating platform, Cellgenic seeks to accelerate market development while supporting physicians practicing within applicable regulatory guidelines.

This initiative also strengthens the strategic relationship between Cellgenic’s commercial organization and ISSCA’s physician education platform. Through conferences, advanced certification programs, and hands-on training events, the Company expects to significantly increase physician engagement while supporting continued adoption of regenerative medicine technologies.

The Argentina expansion aligns with RMTG’s broader strategy of building an integrated global regenerative medicine ecosystem that combines physician education, biologics commercialization, laboratory capabilities, and international distribution. The Company currently operates across more than 30 countries and continues expanding its commercial footprint through strategic regional hubs.

“We are not simply entering another country,” added Christensen. “We are establishing the infrastructure necessary to support long-term physician education, commercialization, scientific collaboration, and continued expansion throughout Latin America. We believe Argentina will become an important cornerstone of Cellgenic’s international growth strategy for years to come.”

About Cellgenic

Cellgenic, a division of Global Stem Cells Group and Regenerative Medical Technology Group (OTC: RMTG), develops and commercializes regenerative medicine technologies, biologics, cell therapy products, exosomes, peptides, and related medical solutions for physicians and clinics worldwide.

About Regenerative Medical Technology Group

Regenerative Medical Technology Group, Inc. (OTC: RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated commercial expansion, future physician adoption, expected market opportunities, operational growth, revenue potential, geographic expansion, and other statements that are not historical facts. Actual results may differ materially due to various risks and uncertainties, including regulatory developments, market acceptance, operational execution, competitive conditions, economic factors, and other risks detailed in the Company’s filings with OTC Markets and applicable regulatory authorities.

Miami, FL / Global — March 22nd, 2026

Global Stem Cells Group, operating under RMTG, today announced the official launch of the ISSCA Mobile App, a next-generation digital platform designed to unify physician education, clinical collaboration, and professional networking across the rapidly growing regenerative and longevity medicine sectors.

The app has been developed by ISSCA (International Society for Stem Cell Application), the Company’s education and training division, and represents a strategic move toward building the digital infrastructure layer of regenerative medicine globally.

A Strategic Shift Toward Platform-Based Medicine

With this launch, Global Stem Cells Group transitions beyond traditional clinical services and training into a technology-enabled ecosystem model, connecting physicians, education, and clinical innovation through a centralized digital platform.

The ISSCA App enables physicians worldwide to:

• Access on-demand regenerative medicine training and protocols
• Participate in live and recorded global webinars
• Track certifications and professional credentials
• Engage in physician-only collaboration forums
• Stay connected to ISSCA events, summits, and certification programs

This positions the Company to expand its role from a service provider into a scalable digital platform company within the healthcare and biotechnology sector.

Expanding a Global Physician Network

Global Stem Cells Group operates internationally through its subsidiary network, providing regenerative medicine solutions, physician training, and clinical services across multiple regions.

Through ISSCA, the Company has built a global physician ecosystem spanning more than 30 countries, combining education, clinical protocols, and product distribution into a unified model.

The ISSCA App now digitizes and scales this network, allowing for continuous engagement rather than episodic interaction through conferences and in-person training.

Industry Context: Digital Transformation of Medical Education

The launch comes amid a broader transformation in healthcare, where:

• Physicians increasingly demand on-demand, mobile-first education
• Clinical knowledge is evolving rapidly, especially in regenerative and longevity medicine
• Digital communities are replacing traditional, fragmented learning models

By consolidating education, certification, and networking into a single platform, the ISSCA App addresses a critical gap in the market:

continuous, real-time access to evolving medical knowledge and peer collaboration.

Executive Commentary

Benito Novas, CEO of Global Stem Cells Group, commented:

“The future of medicine is not only biological—it is connected. With the ISSCA App, we are creating a global digital network where physicians can learn, collaborate, and evolve in real time. This is a foundational step toward building the infrastructure of next-generation medicine.”

Competitive Positioning

The ISSCA App differentiates itself through:

• A specialized focus on regenerative and longevity medicine
• Integration of education, certification, and networking into one platform
• Direct access to global experts and real-world clinical protocols
• A scalable model designed to support thousands of physicians globally

This positions Global Stem Cells Group as one of the few companies combining:

• Clinical services
• Physician education
• Biologic product commercialization
• Digital platform infrastructure

Strategic Synergy with ISSCA AI™

The ISSCA App also lays the groundwork for integration with ISSCA AI™, the Company’s clinical intelligence platform.

Together, these technologies will enable a unified ecosystem where physicians can:

• Learn through the ISSCA App
• Connect and collaborate globally
• Optimize clinical decisions using AI-driven tools

This convergence represents a key step toward building a fully integrated, AI-powered regenerative medicine network.

Market Opportunity

Global Stem Cells Group operates within a rapidly expanding regenerative medicine and digital health market, driven by:

• Increased adoption of biologics and cellular therapies
• Growing demand for personalized and longevity-focused treatments
• The need for scalable physician education and support systems

The ISSCA App enhances the Company’s ability to:

• Drive physician engagement and retention
• Increase participation in training and certification programs
• Expand its global footprint through digital channels

About Global Stem Cells Group (OTC: RMTG)

Global Stem Cells Group, operating under RMTG, is a regenerative medicine company providing physician training, clinical services, biologics, and turnkey solutions worldwide.

Through its ISSCA division, the Company has established a global network of physicians and continues to expand its footprint across emerging medical markets.

Media & Investor Contact

[sarah Barroso ]
Investor Relations: [Info@stemcellsgroup.com ]
Website: www.stemcellsgroup.com

Forward-Looking Statements

This press release contains forward-looking statements regarding future developments, growth, and market opportunities. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected.

Miami, FL / Global — February 12, 2026

Global Stem Cells Group, a publicly traded leader in regenerative medicine and advanced cellular therapies, today announced the official launch of ISSCA AI™ Clinical Intelligence Platform, a next-generation artificial intelligence system developed by its education and innovation division, ISSCA (International Society for Stem Cell Application).

This milestone marks a transformative step in the convergence of artificial intelligence, regenerative medicine, and clinical operations, positioning the company at the forefront of the next evolution in healthcare delivery.

A New Category: Clinical Intelligence for Regenerative Medicine

The ISSCA AI™ platform is designed to transform complex clinical data into actionable medical insights, enabling physicians to enhance diagnostic precision, optimize treatment protocols, and streamline practice operations.

Unlike traditional healthcare software, ISSCA AI™ represents a comprehensive clinical intelligence ecosystem, integrating:

• AI-assisted diagnostics and patient intake
• Intelligent regenerative protocol design
• Predictive analytics and biological age modeling
• Patient follow-up automation and engagement systems
• Full clinical workflow and practice optimization

This approach aligns with the global shift toward AI-powered healthcare systems that augment physician decision-making while reducing administrative burden and improving patient outcomes.

Strategic Positioning: From Education to Infrastructure

With over 15 years of global leadership in physician training across more than 30 countries, ISSCA now evolves from an education-driven organization into a technology-enabled clinical infrastructure provider.

The ISSCA AI™ platform is purpose-built for:

• Regenerative medicine clinics
• Longevity and anti-aging centers
• Integrative and functional medicine practices
• Advanced biologics and cellular therapy providers

By embedding AI into clinical workflows, the platform enables practitioners to scale personalized medicine while maintaining clinical control and scientific rigor.

Industry Context: AI as the Next Operating System of Medicine

The launch comes at a pivotal moment in healthcare, where artificial intelligence is rapidly becoming foundational infrastructure:

• Over two-thirds of physicians already use some form of AI in clinical practice
• AI-driven tools are demonstrating measurable improvements in efficiency, accuracy, and patient throughput
• Clinical AI systems are increasingly capable of real-time decision support, predictive modeling, and workflow automation

Industry experts project that AI will become the operating system of modern medical practices, particularly in data-intensive fields such as regenerative and longevity medicine.

ISSCA AI™ directly addresses this shift by providing a unified platform that bridges clinical insight, operational efficiency, and patient experience.

Executive Commentary

Benito Novas, CEO of Global Stem Cells Group, commented:

“The future of medicine is not just biological—it is computational. With ISSCA AI™, we are empowering physicians with a system that enhances their intelligence, not replaces it. This is about enabling better decisions, better outcomes, and ultimately, better medicine at scale.”

Competitive Differentiation

ISSCA AI™ distinguishes itself from existing healthcare AI tools through:

• Domain specialization in regenerative and longevity medicine
• Integration of clinical, operational, and patient engagement layers
• Alignment with real-world physician workflows, not just academic models
• A global distribution network through ISSCA’s physician ecosystem

This positions Global Stem Cells Group to capture value not only as a clinical and educational leader, but as a technology innovator in precision medicine infrastructure.

Market Opportunity

The global AI in healthcare market is experiencing rapid expansion, driven by:

• Rising demand for personalized medicine
• Increasing clinical data complexity
• Physician burnout linked to administrative overload
• The need for scalable, technology-enabled care models

ISSCA AI™ addresses these challenges directly, offering a platform capable of increasing efficiency, reducing cognitive load, and enhancing clinical outcomes simultaneously.

Forward-Looking Vision

The launch of ISSCA AI™ represents the first phase of a broader strategic roadmap, including:

• Expansion into digital twins and predictive longevity modeling
• Integration with cellular therapy and biologics platforms (Cellgenic)
• Development of AI-driven clinical networks across global markets
• Continuous learning systems powered by real-world clinical data

About Global Stem Cells Group

Global Stem Cells Group is a global leader in regenerative medicine, combining clinical services, physician training, and biotechnology commercialization. Through its divisions—including ISSCA (International Society for Stem Cell Application) and Cellgenic—the company operates at the intersection of science, education, and innovation.

Media & Investor Contact

Sarah Barroso
Info@stemcellsgroup.com
[Website: www.stemcellsgroup.com]

Forward-Looking Statements

This press release contains forward-looking statements regarding future developments, performance, and market opportunities. Actual results may differ materially based on regulatory, technological, and market conditions.

Miami, Florida — Cellgenic, the biologics manufacturing division of Global Stem Cells Group (GSCG), today announced that its advanced biologics manufacturing facility in Cancún, Mexico, has officially commenced full operations. Following its initial introduction to the international medical community during the ISSCA Global Regenerative Medicine Summit in September 2025, the laboratory is now actively producing and distributing biologic products to authorized medical professionals and institutions in international markets where local regulations permit.

The operational launch represents an important step in what Cellgenic hopes will be a long-term effort to support responsible access to regenerative biologics through transparent manufacturing processes, ethical sourcing, and internationally guided quality practices.

Purpose-Built Facility Designed for International Distribution

The Cancún laboratory was designed as a centralized manufacturing hub intended to support physicians, clinics, wellness centers, and research institutions seeking access to advanced biologics. The facility incorporates modular cleanroom environments, controlled cold-chain logistics, structured batch documentation, and donor traceability systems developed with reference to AATB-aligned practices and COFEPRIS-guided operational frameworks.

To Cellgenic’s knowledge, this facility is the first in Cancún developed specifically for the external manufacturing and distribution of biologics, rather than production limited to internal or single-site clinical use.

Xeno-Free Manufacturing Philosophy

All biologics produced at the Cancún facility are manufactured under xeno-free conditions, meaning that no animal-derived components are used at any stage of production. Cellgenic’s manufacturing philosophy emphasizes the use of human-origin materials, controlled inputs, and documented sourcing processes.

While Cellgenic does not make claims regarding clinical outcomes, the company believes that xeno-free manufacturing practices may support broader international acceptance and alignment with evolving regulatory expectations in multiple regions. The company hopes that this approach will offer physicians and institutions additional confidence when evaluating biologics for educational, investigational, or authorized clinical use.

Integration with Cellular Hope Institute and ISSCA

The facility operates in close coordination with the Cellular Hope Institute, a clinical and educational center operating under Global Stem Cells Group. based in Cancún, as well as with ISSCA (International Society for Stem Cell Application), the educational division of Global Stem Cells Group.

Through this integration, visiting physicians and researchers participating in ISSCA-accredited programs may observe manufacturing workflows, engage in hands-on educational sessions, and participate in structured clinical discussions related to biologics handling and responsible application.

“We expect this facility to play a meaningful role in our integrated model of manufacturing, education, and clinical collaboration,” said Sarah Barroso, Managing Director of Cellgenic. “By aligning our laboratory operations with the Cellular Hope Institute and ISSCA’s educational platform, we hope to contribute to greater transparency, consistency, and professional dialogue within the regenerative medicine field.”

Current Manufacturing Capabilities and Pipeline Development

As of January 2026, the Cancún facility is producing the following biologics for authorized distribution:

• Exosome Flow Series – Liquid exosomes available in multiple concentrations
• Lyophilized Exosomes – Prepared for topical and localized applications
• Umbilical Cord–Derived Mesenchymal Stem Cells (MSCs) – Cryopreserved and culture-expanded
• Natural Killer (NK) Cells – Produced under controlled freezing and handling protocols
• Allogeneic Fibroblasts – Intended for aesthetic and research-oriented applications
• Sterile Diluents – Including bacteriostatic water and saline solutions

Cellgenic has also outlined plans to expand its capabilities during 2026 to include:

• Exosome–peptide combination formulations
• Multi-peptide blended delivery formats
• Cell-free conditioned media (secretome)
• Cryopreserved cell banking services
• Private-label and white-label manufacturing programs

All products are accompanied by batch documentation, donor screening records, and handling guidelines. Cellgenic emphasizes that its biologics are not intended to diagnose, treat, cure, or prevent any disease and are supplied exclusively to authorized professionals and institutions in compliance with local regulations.

Commitment to Responsible Global Expansion

As part of its international growth strategy, Cellgenic has introduced an Authorized Distributor Program designed for qualified partners operating in compliant markets. The program is structured to support long-term collaboration through educational resources, standardized documentation, and regional alignment initiatives.

“We believe this facility reflects our continued focus on responsibility, quality, and long-term infrastructure,” said Dave Christensen, CEO of Global Stem Cells Group. “Our goal has never been rapid expansion without structure. We hope this laboratory will support physicians and institutions seeking consistent, well-documented biologics produced under carefully designed conditions.”

About Cellgenic

Cellgenic is the biologics manufacturing and innovation division of Global Stem Cells Group, a multinational organization engaged in regenerative medicine education, clinical collaboration, and biologics development. With operations and partnerships across North America, Latin America, Europe, and Asia, Cellgenic focuses on producing biologics under transparent, xeno-free, and compliance-oriented frameworks to support responsible use in diverse international settings.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to the operational launch and expansion of capabilities at our Cancún, Mexico biologics manufacturing facility. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. 

Miami, Florida – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), have successfully concluded two major events in their 2025 international educational series: the International Regenerative Medicine Conference in Bogotá, Colombia, and the International Regenerative Medicine Conference and Certifications in Cancún, Mexico.

Both gatherings brought together physicians, researchers, and healthcare professionals from across the world to exchange knowledge and explore the latest advancements in regenerative medicine, cellular therapies, and peptide science. With these two conferences, ISSCA has now held more than twelve international conferences so far this year, reaffirming its ongoing commitment to physician education, scientific collaboration, and the responsible advancement of regenerative technologies.

---

Conference and Scientific Highlights from Colombia

The Bogotá Conference was held on October 24–25, 2025, at the W Hotel, featuring a comprehensive scientific agenda developed by the ISSCA Scientific Committee. International experts presented cutting-edge topics such as exosomes, peptides, NAD+, and MUSE cells.

Distinguished speakers included Lauren Fitzgerald, MD (USA), on peptide-based clinical optimization; Brandon Sassouni, MSc (USA), on MUSE cells and exosome therapeutics; Andrea Lapeire, MD (Argentina), ISSCA LATAM Director; Richard Silva, DO (USA), on functional regenerative applications; and Rafael Moguel, MD (Mexico), on cardiovascular regeneration.

The conference concluded with MedConnect, ISSCA’s signature international networking cocktail event, featuring an upscale social experience with canapés, beverages, live music, and performance showcases, while fostering high-level collaboration between physicians, researchers, and regenerative medicine organizations worldwide.

---

Conference and Certifications in Cancún

From November 7–9, 2025, ISSCA and GSCG hosted the International Regenerative Medicine Conference in Cancún at the InterContinental Presidente Cancún Resort, followed by three specialized certification programs:

1. Stem Cell Therapies Certification – covering clinical applications of mesenchymal and MUSE cells, exosome integration, and regenerative treatment protocols.
   
   
2. Advanced Peptide Certification – focused on molecular mechanisms, clinical design, and patient-oriented peptide protocols for longevity, performance, and metabolic balance.
   
   
3. MSK / Sports Medicine Certification – emphasizing regenerative techniques for orthopedic and sports-related injuries, including PRP, exosome, and peptide-based recovery strategies.
   
   

Keynote presentations were delivered by Greg Jones, NMD, ABAAHP (USA) on peptide-based preventive medicine; Jason Pencek, DC, FNP (USA) on mitochondrial repair and integrative peptide strategies; Prof. Dr. Roni Moya (Portugal) on immune engineering and translational applications; Márcio Kume, MD, PhD (Brazil) on musculoskeletal regeneration and orthopedic innovation; Wajid Burad, MD (Mexico) on sports performance and non-surgical interventions; and Brandon Sassouni, MSc (USA) on advancements in universal cell applications.

“These programs are designed to provide physicians with practical, evidence-based tools that they can apply directly in their medical practice,” said Benito Novas, Founder of ISSCA. “We believe that combining scientific discussion with structured certifications ensures a more complete and responsible approach to regenerative medicine education.”

Dave Christensen, CEO of Regenerative Medical Technology Group Corp. (parent to GSCG), added:

“The participation and engagement seen in both Colombia and Cancún demonstrate the strong interest among physicians in expanding their knowledge in regenerative and peptide-based medicine. These events continue to strengthen the foundation for ongoing collaboration between science and clinical practice.”

---

Upcoming Educational Events

Before the end of the year, ISSCA and GSCG will continue their educational calendar with two additional international conferences:

• Lima, Peru – November 28–30, 2025
  
  
• San Juan, Puerto Rico – December 5–6, 2025
  
  

Both upcoming conferences will maintain the organization’s multidisciplinary format, combining theoretical lectures, certification modules, and hands-on workshops covering stem cell therapy, peptide applications, and musculoskeletal repair.

Looking ahead, Global Stem Cells Group and ISSCA are preparing a robust educational program for 2026, which already includes events in more than 15 countries across Latin America, Europe, the Middle East, and Asia. The goal is to continue facilitating responsible scientific education, networking, and professional development for physicians dedicated to regenerative and cellular medicine.

---

About the International Society for Stem Cell Application (ISSCA)

ISSCA, a division of Global Stem Cells Group, focuses on education, certification, and professional development in regenerative medicine and cellular therapies. With over 15 years of global experience, ISSCA designs and delivers multidisciplinary programs that connect scientific innovation with real-world clinical application.

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is an international organization dedicated to advancing regenerative medicine through research, product development, and physician education. The company provides access to the latest biologic innovations, clinical tools, and specialized training to support the safe and effective practice of regenerative therapies.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida —CELLGENIC, a division of Global Stem Cells Group and a recognized name in regenerative medicine, is pleased to announce the successful introduction of its Peptide Pen product line, officially presented during the Global Stem Cells Group Global Summit held in Cancún. The new line represents an important step toward simplifying and modernizing peptide therapy within the field of regenerative and longevity medicine.

The CELLGENIC Peptide Pen series was designed to offer physicians a more practical approach to peptide therapy. Each pre-loaded device contains synergistic peptide formulations that we believe may support various clinical goals such as recovery, immune balance, metabolic optimization, and overall wellness. By integrating multiple compounds into a single, ready-to-use pen, we hope to help physicians streamline their protocols while maintaining consistency and ease of use.

“Our mission has always been to make advanced biologics more accessible and clinically practical,” said Benito Novas, Founder of Global Stem Cells Group. “We believe the Peptide Pen line reflects this philosophy by providing a convenient and reliable tool for physicians dedicated to regenerative and performance medicine.”

Since its debut at the Global Summit, the Peptide Pen line has received encouraging interest from physicians attending the event and from CELLGENIC’s international partners. The company believes this positive reception reflects the growing recognition of peptide-based approaches within medical practice.

“We are very encouraged by the response from physicians who attended the Summit,” said Sarah Barroso, Managing Director of CELLGENIC. “We expect the Peptide Pen to continue generating interest among professionals seeking innovative yet practical tools to integrate into their existing clinical programs.”

---

A Growing Movement in Modern Medicine

Across the world, peptide therapy is gaining attention among physicians who seek to work at the intersection of biology, longevity, and personalized medicine. These short chains of amino acids are being studied for their potential roles in supporting cellular repair, optimizing metabolism, and promoting balanced physiological function.

At CELLGENIC, we believe peptide therapy represents one of the most promising frontiers in the evolution of regenerative and preventive medicine. As healthcare continues to shift toward individualized and performance-based care, peptide integration may help physicians design more targeted and adaptive therapeutic programs.

Through innovation and education, we hope to contribute to this global movement by offering tools that are practical, well-supported, and aligned with responsible medical practice.

---

Commitment to Education and Ethical Practice

The launch of the Peptide Pen line also aligns with CELLGENIC’s ongoing educational mission through the International Society for Stem Cell Application (ISSCA), which continues to promote physician training in advanced biologic and peptide-based therapies.

CELLGENIC sells its products exclusively to licensed physicians and medical professionals, ensuring that all peptide applications remain within a qualified and ethical clinical framework.

Through this initiative, CELLGENIC continues to expand its presence in regenerative medicine, maintaining a focus on innovation, education, and international collaboration.

---

About CELLGENIC

CELLGENIC, a division of Global Stem Cells Group, focuses on the development and distribution of advanced biologic products including exosomes, cell-based systems, and peptide solutions. With more than 15 years of experience, CELLGENIC aims to support physicians worldwide through innovation, training, and reliable access to next-generation medical technologies.

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.

More information:

www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Cancún, Mexico — September 14, 2025. The Regenerative Medicine Global Summit 2025, organized by the International Society for Stem Cell Application (ISSCA) — the world’s largest organization dedicated to training physicians in regenerative medicine — successfully took place on September 12–13 at Secrets The Vine Cancún.

With a full house of participants from more than 30 countries, including representatives from Malaysia, Vietnam, Tajikistan, Ghana, South Africa, Japan, the United States, Spain, Italy and multiple nations, Cancún became the epicenter of innovation and collaboration in regenerative medicine.

---

Leadership Reflections

“This summit proved that regenerative medicine is no longer confined by borders. With physicians and scientists gathered from every continent, we are setting a global standard in how knowledge is shared and therapies are advanced,”
 — Dave Christensen, CEO of Global Stem Cells Group (GSCG)

“Our goal is to close the gap between research and clinical practice, giving physicians the tools to deliver the medicine of tomorrow, today. This summit is not only about science; it is about shaping a healthier future for patients,”
 — Benito Novas, Founder of ISSCA

“With participants from more than 30 countries, Cancún truly became a hub of regenerative medicine. Between the scientific sessions, the workshops, and the networking opportunities, this event proved Mexico’s growing leadership in biotechnology and medical education,”
 — Sarah Barroso, Managing Director, CELLGENIC

---

Day 1: Scientific Conferences

The first day offered a full agenda of keynote lectures, where global experts presented disruptive insights into the future of regenerative medicine:

• Prof. Mari Dezawa (Japan): MUSE Cells™ and Their Exosomes: The Next Frontier in Immune-Modulating Therapies
  ING Agenda Cancun SUMMIT CORT
  
  
• Dr. Rafael González (USA): Beyond the Hype: The Real-World Evidence Behind NK Cells and Stem Cell Therapies
  
• Dr. Matt Cook (USA): Precision Ultrasound-Guided Interventions
  
  
• Dr. Alan Gaveck (USA): Engineering the Immune System: From Lab to Clinic
  
  
• Jason Pencek (USA): Next-Gen Biohacking: Cellular Strategies for Repair, Performance & Healthspan
  
  
• Prof. Dato’ Sri Dr. Mike Chan (Malaysia/Europe): Bioregenerative Longevity and Immunomodulation in Anti-Aging Medicine
  
• Dr. Keith L. March (USA): The Rise of Cell-Free Regenerative Therapies: Clinical-Grade Secretomes as the Future of Medicine
  
• Dr. Greg Jones (USA): Peptides, Hormones, and Functional Protocols to Reverse Chronic Degeneration
  
• Dr. Richard Silva (USA): Sports Optimization with Cellular Medicine
  
• Dr. Jeff Wiegers (USA): Pain Management Reimagined: Biologics, Peptides, and Guided Injections
  
• Dr. Vincenzo Di Donna (Italy): Organoids and Regenerative Ozone Therapy to Support Stem Cell Therapy
  
• Prof. Roni Moya (Portugal): Innovations in Regenerative Biomedicine
  
• Prof. Jonathan Lakey (USA): Advances in Cellular Transplantation
  
• Dr. Matthew Halpert (USA): Cancer as an Immunological Disorder: A New Weapon in the Fight
  

The program also featured a select exhibitor area with booths from CELLGENIC, Eleve Health, Immunocine, Cellular Hope Institute, MUSE Cells Innovation, and ISSCA, allowing participants to discover new therapies, devices, and upcoming opportunities.

The day concluded with MedConnect, ISSCA’s signature networking event, hosted at the rooftop of Royalton Chic Cancún. This gathering allowed physicians to connect with peers in their field and foster collaborations in an exclusive setting overlooking the Caribbean.

---

Day 2: Hands-On Workshops and Certifications

The second day was exclusively reserved for 150 certified participants, divided into five simultaneous workshops designed for practical, hands-on training:

1. MUSE Cells Innovation — Prof. Mari Dezawa, Dr. Jeff Wiegers, and Prof. Jonathan Lakey led a session comparing MUSE Cells with mesenchymal stem cells, exploring applications in orthopedics, aesthetics, and immunology.
   
   
2. NK Cells & Advanced Cellular Therapies — In collaboration with ImmunoSyn at ReHealth’s laboratory, guided by Dr. Rafael González and Dr. Matthew Halpert. Participants later visited the Cellgenic laboratory to observe stem cell manufacturing processes.
   
   
3. Peptide Therapy Workshop — Jason Pencek and Dr. Greg Jones conducted a comprehensive workshop on therapeutic peptides, dosing strategies, and protocols for longevity, aesthetics, and chronic degeneration.
   
   
4. Musculoskeletal & Sports Medicine — Directed by Dr. Richard Silva, Dr. Wahid Burad, and Dr. Vincenzo Di Donna, focusing on sports optimization, musculoskeletal regeneration, and longevity protocols.
   
   
5. Advanced Aesthetics — Presented by Prof. Roni Moya and Prof. Mike Chan, covering exosomes, peptides, PRP, and regenerative aesthetic therapies for facial rejuvenation and tissue regeneration.
   
   

---

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a global organization with over 15 years of experience promoting education, research, and certification in regenerative medicine. With presence in more than 20 countries, ISSCA drives the professionalization of the field through international summits, academic programs, and clinical alliances.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG), an international organization dedicated to advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its CELLGENIC brand into the Dominican Republic. This development is viewed as an important step in GSCG’s broader efforts to make advanced biologics and physician training increasingly accessible across Latin America and the Caribbean.

A Strategic Expansion in the Caribbean

Through this agreement, CELLGENIC hopes to introduce its exosome products and mesenchymal stem cell (MSC) therapies to the Dominican Republic, with the expectation of gradually expanding its product line to include additional advanced cellular therapies. This initiative is also expected to be supported by education and certification programs for physicians, so that the use of regenerative medicine technologies may be carried out responsibly and in line with international best practices.

“We are hopeful that extending CELLGENIC’s presence into the Dominican Republic will represent another meaningful step toward our mission,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Our aim is to provide physicians with access to promising biologics alongside educational opportunities. By working closely with our local partners, we expect to help create an environment where regenerative medicine may continue to grow in a safe and ethical way.”

Local Leadership and Collaboration

The rollout in the Dominican Republic will be guided by Dra. Patria González, CELLGENIC’s official representative in the country. Together with her partners, Dr. Faddis Will and Irma Sánchez, Dra. González will support the introduction of CELLGENIC products to the local market.

“After years of development, we are excited about the opportunity to bring CELLGENIC products to physicians and patients in the Dominican Republic,” said Dra. González. “We believe strongly in the potential of regenerative medicine and we hope that exosomes, MSCs, and other advanced therapeutics will become important tools in our local healthcare system. Our expectation is that this collaboration will allow us to do so in alignment with international standards.”

Education at the Core

In addition to product introduction, ISSCA—the educational division of GSCG—plans to organize certification programs to support physicians in their training and clinical application of these protocols.

“Beyond the products themselves, we hope to make education a central part of this initiative,” added Novas. “We expect that properly trained physicians will be able to evaluate and apply these therapies in ways that may benefit their patients.”

Looking Ahead

As part of this collaboration, CELLGENIC and ISSCA will support the upcoming ISSCA 2026 event in the Dominican Republic, scheduled for the first quarter of 2026. The event is anticipated to bring together international experts, local physicians, and healthcare leaders to discuss new opportunities for regenerative medicine in the Caribbean.

“We are hopeful that this partnership will open the door to innovation in our country,” added Irma Sánchez. “The Dominican Republic is not only a beautiful place but also a healthcare market that we believe is ready to explore these possibilities. We expect that physicians and patients alike will benefit from the knowledge and products introduced through this collaboration.”

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.

More information:
www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG), an international organization focused on advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its operations into Brazil through a new strategic representation agreement with Julius Ladeira. This collaboration is anticipated to bring the full scope of GSCG’s divisions—including ISSCA (International Society for Stem Cell Application) and CELLGENIC, its biologics manufacturing arm—into one of the most dynamic healthcare markets in Latin America.

A New Chapter for Regenerative Medicine in Brazil

Brazil, home to more than 600,000 physicians, has long been recognized as a country with significant potential for regenerative medicine. It is estimated that nearly 50,000 physicians are already engaged in preventive and regenerative practices, with approximately 30,000 incorporating these approaches into their daily work. GSCG believes that the introduction of its educational programs, biologic products, and network of centers of excellence may help align Brazil more closely with the latest global developments in cellular therapies.

“We are hopeful that this new representation will mark the beginning of a long-term partnership that benefits both physicians and patients in Brazil,” said Benito Novas, CEO of Global Stem Cells Group, Founder of ISSCA and CELLGENIC. “For years, many Brazilian physicians have traveled abroad to train with ISSCA and to access advanced technologies. Now, we expect to bring these opportunities directly into the country, creating local access to training, certification, and biologic solutions.”

Local Leadership for National Impact

The agreement appoints Julius Ladeira as the official representative of Global Stem Cells Group in Brazil. He will oversee the introduction of ISSCA educational programs, CELLGENIC’s biologic products, and GSCG’s broader initiatives into the local market.

“It is with great satisfaction that we welcome ISSCA, CELLGENIC, and the Global Stem Cells Group into Brazil,” said Julius Ladeira. “We expect this partnership to be of great importance not only for the Group but also for Brazil as a whole. Our market has extraordinary potential, and we believe this initiative may bring real opportunities for growth and collaboration.”

Upcoming Conference in São Paulo

As part of this expansion, ISSCA has already scheduled its first major educational event in Brazil, set to take place in São Paulo on October 2–3, 2025. The conference is expected to bring together national and international experts, providing physicians with access to hands-on training, certification programs, and the latest insights in regenerative medicine.

“We are hopeful that this event will serve as the first of many collaborative milestones in Brazil,” added Novas. “Our expectation is to create a sustainable platform where education and innovation can come together for the benefit of physicians and their patients.”

---

About Global Stem Cells Group and CELLGENIC
 Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with operations in more than 40 countries. Its divisions cover clinical research, physician education, and biologics commercialization.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, platelet-rich plasma kits, and other cellular solutions—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.

More information:
www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.